1. Home
  2. AVNS vs IMMP Comparison

AVNS vs IMMP Comparison

Compare AVNS & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Avanos Medical Inc.

AVNS

Avanos Medical Inc.

N/A

Current Price

$12.97

Market Cap

521.7M

Sector

Health Care

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

HOLD

Current Price

$2.76

Market Cap

410.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AVNS
IMMP
Founded
2014
1987
Country
United States
Australia
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
521.7M
410.7M
IPO Year
2014
2012

Fundamental Metrics

Financial Performance
Metric
AVNS
IMMP
Price
$12.97
$2.76
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
519.4K
161.2K
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
81.59
N/A
EPS
N/A
N/A
Revenue
$701,200,000.00
N/A
Revenue This Year
$3.28
$382.75
Revenue Next Year
$4.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.95
N/A
52 Week Low
$9.30
$1.32
52 Week High
$15.68
$3.53

Technical Indicators

Market Signals
Indicator
AVNS
IMMP
Relative Strength Index (RSI) 37.90 49.22
Support Level $12.75 $2.74
Resistance Level $13.18 $3.24
Average True Range (ATR) 0.58 0.13
MACD -0.27 -0.01
Stochastic Oscillator 6.48 53.22

Price Performance

Historical Comparison
AVNS
IMMP

About AVNS Avanos Medical Inc.

Avanos Medical Inc is a United States-based company that develops and sells medical devices and related services globally. Its operating and reportable segment provides medical device products to healthcare providers and patients. The company has now changed two franchises: has combined Chronic Care and Pain Management franchises into a single commercial organization focused on the Digestive Health and Pain Management and Recovery product categories that generate its revenue from its Chronic Care franchise and in North America.

About IMMP Immutep Limited

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: